Titre : Anticorps

Anticorps : Questions médicales fréquentes

Termes MeSH sélectionnés :

Infliximab

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment détecte-t-on les anticorps dans le sang ?

On utilise des tests sérologiques comme l'ELISA pour mesurer les anticorps.
Anticorps Tests sérologiques
#2

Quels tests sont utilisés pour les anticorps spécifiques ?

Des tests comme l'immunofluorescence ou les tests d'agglutination sont utilisés.
Anticorps Immunofluorescence
#3

Les anticorps peuvent-ils indiquer une infection ?

Oui, la présence d'anticorps spécifiques peut indiquer une infection antérieure.
Anticorps Infection
#4

Qu'est-ce qu'un titre d'anticorps ?

C'est une mesure de la concentration d'anticorps dans le sang, indiquant l'immunité.
Anticorps Immunité
#5

Les anticorps peuvent-ils être détectés chez les nouveau-nés ?

Oui, les anticorps maternels peuvent être détectés chez les nouveau-nés.
Anticorps Nouveau-né

Symptômes 5

#1

Quels symptômes indiquent une réponse immunitaire ?

Fièvre, fatigue, et inflammation peuvent indiquer une réponse immunitaire active.
Réponse immunitaire Symptômes
#2

Les anticorps causent-ils des symptômes ?

Non, ce sont les maladies ou infections que les anticorps combattent qui causent des symptômes.
Anticorps Maladies infectieuses
#3

Comment les anticorps affectent-ils les allergies ?

Les anticorps IgE sont impliqués dans les réactions allergiques, provoquant des symptômes.
Anticorps Allergies
#4

Les anticorps peuvent-ils causer des maladies auto-immunes ?

Oui, des anticorps peuvent attaquer les tissus sains, entraînant des maladies auto-immunes.
Anticorps Maladies auto-immunes
#5

Quels anticorps sont liés aux infections virales ?

Les anticorps IgM et IgG sont souvent associés aux infections virales.
Anticorps Infections virales

Prévention 5

#1

Comment les vaccins stimulent-ils la production d'anticorps ?

Les vaccins introduisent des antigènes, entraînant la production d'anticorps spécifiques.
Vaccins Anticorps
#2

Les anticorps peuvent-ils être transférés par le lait maternel ?

Oui, les anticorps maternels sont transférés au bébé par le lait maternel, offrant une protection.
Anticorps Lait maternel
#3

Comment maintenir un système immunitaire fort ?

Une alimentation équilibrée, l'exercice et le sommeil aident à maintenir un système immunitaire fort.
Système immunitaire Prévention
#4

Les anticorps peuvent-ils être utilisés pour prévenir le COVID-19 ?

Des traitements par anticorps monoclonaux sont utilisés pour prévenir les formes graves du COVID-19.
COVID-19 Anticorps monoclonaux
#5

Les anticorps sont-ils efficaces contre toutes les infections ?

Non, leur efficacité dépend du type d'infection et de la réponse immunitaire individuelle.
Anticorps Infections

Traitements 5

#1

Comment les anticorps sont-ils utilisés en thérapie ?

Des anticorps monoclonaux sont utilisés pour traiter diverses maladies, y compris le cancer.
Anticorps monoclonaux Thérapie
#2

Les anticorps peuvent-ils être administrés par injection ?

Oui, les anticorps peuvent être administrés par injection pour traiter certaines maladies.
Anticorps Injection
#3

Qu'est-ce que l'immunothérapie par anticorps ?

C'est un traitement qui utilise des anticorps pour renforcer la réponse immunitaire contre le cancer.
Immunothérapie Anticorps
#4

Les anticorps peuvent-ils être utilisés pour prévenir des maladies ?

Oui, des anticorps spécifiques peuvent être administrés pour prévenir certaines infections.
Anticorps Prévention des maladies
#5

Quels sont les effets secondaires des traitements par anticorps ?

Les effets secondaires peuvent inclure des réactions allergiques et des infections.
Anticorps Effets secondaires

Complications 5

#1

Quels sont les risques d'une surproduction d'anticorps ?

Une surproduction peut entraîner des maladies auto-immunes ou des allergies graves.
Anticorps Maladies auto-immunes
#2

Les anticorps peuvent-ils causer des réactions allergiques ?

Oui, certains anticorps peuvent provoquer des réactions allergiques en réponse à des allergènes.
Anticorps Réactions allergiques
#3

Quelles complications peuvent survenir avec des anticorps monoclonaux ?

Des infections, des réactions allergiques et des effets secondaires peuvent survenir.
Anticorps monoclonaux Complications
#4

Les anticorps peuvent-ils interférer avec d'autres traitements ?

Oui, certains anticorps peuvent interagir avec d'autres médicaments, affectant leur efficacité.
Anticorps Interactions médicamenteuses
#5

Quelles sont les complications des maladies auto-immunes ?

Les complications incluent des dommages aux organes, des infections et une qualité de vie réduite.
Maladies auto-immunes Complications

Facteurs de risque 5

#1

Quels facteurs augmentent le risque de maladies auto-immunes ?

Des facteurs génétiques, environnementaux et hormonaux peuvent augmenter ce risque.
Facteurs de risque Maladies auto-immunes
#2

Le stress influence-t-il la production d'anticorps ?

Oui, le stress chronique peut affecter la réponse immunitaire et la production d'anticorps.
Stress Anticorps
#3

L'âge influence-t-il la réponse des anticorps ?

Oui, la réponse des anticorps peut diminuer avec l'âge, rendant les personnes âgées plus vulnérables.
Âge Anticorps
#4

Les infections antérieures affectent-elles la production d'anticorps ?

Oui, des infections antérieures peuvent influencer la mémoire immunitaire et la production d'anticorps.
Infections Anticorps
#5

Les habitudes alimentaires influencent-elles les anticorps ?

Oui, une alimentation riche en nutriments peut soutenir la production d'anticorps et la santé immunitaire.
Habitudes alimentaires Anticorps
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Anticorps : Questions médicales les plus fréquentes", "headline": "Anticorps : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Anticorps : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-30", "dateModified": "2025-04-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Anticorps" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Immunoglobulines", "url": "https://questionsmedicales.fr/mesh/D007136", "about": { "@type": "MedicalCondition", "name": "Immunoglobulines", "code": { "@type": "MedicalCode", "code": "D007136", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps anti-idiotypiques", "alternateName": "Antibodies, Anti-Idiotypic", "url": "https://questionsmedicales.fr/mesh/D000888", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-idiotypiques", "code": { "@type": "MedicalCode", "code": "D000888", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.071" } } }, { "@type": "MedicalWebPage", "name": "Anticorps anti-archéens", "alternateName": "Antibodies, Archaeal", "url": "https://questionsmedicales.fr/mesh/D019844", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-archéens", "code": { "@type": "MedicalCode", "code": "D019844", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.107" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antibactériens", "alternateName": "Antibodies, Bacterial", "url": "https://questionsmedicales.fr/mesh/D000907", "about": { "@type": "MedicalCondition", "name": "Anticorps antibactériens", "code": { "@type": "MedicalCode", "code": "D000907", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.125" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Antistreptolysine", "alternateName": "Antistreptolysin", "url": "https://questionsmedicales.fr/mesh/D000989", "about": { "@type": "MedicalCondition", "name": "Antistreptolysine", "code": { "@type": "MedicalCode", "code": "D000989", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.125.288" } } } ] }, { "@type": "MedicalWebPage", "name": "Anticorps bispécifiques", "alternateName": "Antibodies, Bispecific", "url": "https://questionsmedicales.fr/mesh/D018033", "about": { "@type": "MedicalCondition", "name": "Anticorps bispécifiques", "code": { "@type": "MedicalCode", "code": "D018033", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.134" } } }, { "@type": "MedicalWebPage", "name": "Anticorps bloquants", "alternateName": "Antibodies, Blocking", "url": "https://questionsmedicales.fr/mesh/D019138", "about": { "@type": "MedicalCondition", "name": "Anticorps bloquants", "code": { "@type": "MedicalCode", "code": "D019138", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.143" } } }, { "@type": "MedicalWebPage", "name": "Anticorps catalytiques", "alternateName": "Antibodies, Catalytic", "url": "https://questionsmedicales.fr/mesh/D017151", "about": { "@type": "MedicalCondition", "name": "Anticorps catalytiques", "code": { "@type": "MedicalCode", "code": "D017151", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.167" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antifongiques", "alternateName": "Antibodies, Fungal", "url": "https://questionsmedicales.fr/mesh/D000908", "about": { "@type": "MedicalCondition", "name": "Anticorps antifongiques", "code": { "@type": "MedicalCode", "code": "D000908", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.179" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antihelminthe", "alternateName": "Antibodies, Helminth", "url": "https://questionsmedicales.fr/mesh/D000909", "about": { "@type": "MedicalCondition", "name": "Anticorps antihelminthe", "code": { "@type": "MedicalCode", "code": "D000909", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.185" } } }, { "@type": "MedicalWebPage", "name": "Anticorps hétérophiles", "alternateName": "Antibodies, Heterophile", "url": "https://questionsmedicales.fr/mesh/D000910", "about": { "@type": "MedicalCondition", "name": "Anticorps hétérophiles", "code": { "@type": "MedicalCode", "code": "D000910", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.191" } } }, { "@type": "MedicalWebPage", "name": "Anticorps monoclonaux", "alternateName": "Antibodies, Monoclonal", "url": "https://questionsmedicales.fr/mesh/D000911", "about": { "@type": "MedicalCondition", "name": "Anticorps monoclonaux", "code": { "@type": "MedicalCode", "code": "D000911", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps monoclonaux humanisés", "alternateName": "Antibodies, Monoclonal, Humanized", "url": "https://questionsmedicales.fr/mesh/D061067", "about": { "@type": "MedicalCondition", "name": "Anticorps monoclonaux humanisés", "code": { "@type": "MedicalCode", "code": "D061067", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Adalimumab", "alternateName": "Adalimumab", "url": "https://questionsmedicales.fr/mesh/D000068879", "about": { "@type": "MedicalCondition", "name": "Adalimumab", "code": { "@type": "MedicalCode", "code": "D000068879", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.250" } } }, { "@type": "MedicalWebPage", "name": "Alemtuzumab", "alternateName": "Alemtuzumab", "url": "https://questionsmedicales.fr/mesh/D000074323", "about": { "@type": "MedicalCondition", "name": "Alemtuzumab", "code": { "@type": "MedicalCode", "code": "D000074323", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.375" } } }, { "@type": "MedicalWebPage", "name": "Basiliximab", "alternateName": "Basiliximab", "url": "https://questionsmedicales.fr/mesh/D000077552", "about": { "@type": "MedicalCondition", "name": "Basiliximab", "code": { "@type": "MedicalCode", "code": "D000077552", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.407" } } }, { "@type": "MedicalWebPage", "name": "Bévacizumab", "alternateName": "Bevacizumab", "url": "https://questionsmedicales.fr/mesh/D000068258", "about": { "@type": "MedicalCondition", "name": "Bévacizumab", "code": { "@type": "MedicalCode", "code": "D000068258", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.438" } } }, { "@type": "MedicalWebPage", "name": "Brentuximab védotine", "alternateName": "Brentuximab Vedotin", "url": "https://questionsmedicales.fr/mesh/D000079963", "about": { "@type": "MedicalCondition", "name": "Brentuximab védotine", "code": { "@type": "MedicalCode", "code": "D000079963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.469" } } }, { "@type": "MedicalWebPage", "name": "Cétuximab", "alternateName": "Cetuximab", "url": "https://questionsmedicales.fr/mesh/D000068818", "about": { "@type": "MedicalCondition", "name": "Cétuximab", "code": { "@type": "MedicalCode", "code": "D000068818", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.750" } } }, { "@type": "MedicalWebPage", "name": "Daclizumab", "alternateName": "Daclizumab", "url": "https://questionsmedicales.fr/mesh/D000077561", "about": { "@type": "MedicalCondition", "name": "Daclizumab", "code": { "@type": "MedicalCode", "code": "D000077561", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.766" } } }, { "@type": "MedicalWebPage", "name": "Dénosumab", "alternateName": "Denosumab", "url": "https://questionsmedicales.fr/mesh/D000069448", "about": { "@type": "MedicalCondition", "name": "Dénosumab", "code": { "@type": "MedicalCode", "code": "D000069448", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.782" } } }, { "@type": "MedicalWebPage", "name": "Gemtuzumab", "alternateName": "Gemtuzumab", "url": "https://questionsmedicales.fr/mesh/D000079982", "about": { "@type": "MedicalCondition", "name": "Gemtuzumab", "code": { "@type": "MedicalCode", "code": "D000079982", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.790" } } }, { "@type": "MedicalWebPage", "name": "Inotuzumab ozogamicine", "alternateName": "Inotuzumab Ozogamicin", "url": "https://questionsmedicales.fr/mesh/D000080045", "about": { "@type": "MedicalCondition", "name": "Inotuzumab ozogamicine", "code": { "@type": "MedicalCode", "code": "D000080045", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.794" } } }, { "@type": "MedicalWebPage", "name": "Ipilimumab", "alternateName": "Ipilimumab", "url": "https://questionsmedicales.fr/mesh/D000074324", "about": { "@type": "MedicalCondition", "name": "Ipilimumab", "code": { "@type": "MedicalCode", "code": "D000074324", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.798" } } }, { "@type": "MedicalWebPage", "name": "Natalizumab", "alternateName": "Natalizumab", "url": "https://questionsmedicales.fr/mesh/D000069442", "about": { "@type": "MedicalCondition", "name": "Natalizumab", "code": { "@type": "MedicalCode", "code": "D000069442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.813" } } }, { "@type": "MedicalWebPage", "name": "Nivolumab", "alternateName": "Nivolumab", "url": "https://questionsmedicales.fr/mesh/D000077594", "about": { "@type": "MedicalCondition", "name": "Nivolumab", "code": { "@type": "MedicalCode", "code": "D000077594", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.829" } } }, { "@type": "MedicalWebPage", "name": "Omalizumab", "alternateName": "Omalizumab", "url": "https://questionsmedicales.fr/mesh/D000069444", "about": { "@type": "MedicalCondition", "name": "Omalizumab", "code": { "@type": "MedicalCode", "code": "D000069444", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.844" } } }, { "@type": "MedicalWebPage", "name": "Palivizumab", "alternateName": "Palivizumab", "url": "https://questionsmedicales.fr/mesh/D000069455", "about": { "@type": "MedicalCondition", "name": "Palivizumab", "code": { "@type": "MedicalCode", "code": "D000069455", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.860" } } }, { "@type": "MedicalWebPage", "name": "Panitumumab", "alternateName": "Panitumumab", "url": "https://questionsmedicales.fr/mesh/D000077544", "about": { "@type": "MedicalCondition", "name": "Panitumumab", "code": { "@type": "MedicalCode", "code": "D000077544", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.864" } } }, { "@type": "MedicalWebPage", "name": "Ranibizumab", "alternateName": "Ranibizumab", "url": "https://questionsmedicales.fr/mesh/D000069579", "about": { "@type": "MedicalCondition", "name": "Ranibizumab", "code": { "@type": "MedicalCode", "code": "D000069579", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.868" } } }, { "@type": "MedicalWebPage", "name": "Trastuzumab", "alternateName": "Trastuzumab", "url": "https://questionsmedicales.fr/mesh/D000068878", "about": { "@type": "MedicalCondition", "name": "Trastuzumab", "code": { "@type": "MedicalCode", "code": "D000068878", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.875" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ado-trastuzumab emtansine", "alternateName": "Ado-Trastuzumab Emtansine", "url": "https://questionsmedicales.fr/mesh/D000080044", "about": { "@type": "MedicalCondition", "name": "Ado-trastuzumab emtansine", "code": { "@type": "MedicalCode", "code": "D000080044", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.875.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Ado-trastuzumab emtansine", "alternateName": "Ado-Trastuzumab Emtansine", "url": "https://questionsmedicales.fr/mesh/D000080044", "about": { "@type": "MedicalCondition", "name": "Ado-trastuzumab emtansine", "code": { "@type": "MedicalCode", "code": "D000080044", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.875.500" } } }, { "@type": "MedicalWebPage", "name": "Ustékinumab", "alternateName": "Ustekinumab", "url": "https://questionsmedicales.fr/mesh/D000069549", "about": { "@type": "MedicalCondition", "name": "Ustékinumab", "code": { "@type": "MedicalCode", "code": "D000069549", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.937" } } } ] }, { "@type": "MedicalWebPage", "name": "Adalimumab", "alternateName": "Adalimumab", "url": "https://questionsmedicales.fr/mesh/D000068879", "about": { "@type": "MedicalCondition", "name": "Adalimumab", "code": { "@type": "MedicalCode", "code": "D000068879", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.250" } } }, { "@type": "MedicalWebPage", "name": "Alemtuzumab", "alternateName": "Alemtuzumab", "url": "https://questionsmedicales.fr/mesh/D000074323", "about": { "@type": "MedicalCondition", "name": "Alemtuzumab", "code": { "@type": "MedicalCode", "code": "D000074323", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.375" } } }, { "@type": "MedicalWebPage", "name": "Basiliximab", "alternateName": "Basiliximab", "url": "https://questionsmedicales.fr/mesh/D000077552", "about": { "@type": "MedicalCondition", "name": "Basiliximab", "code": { "@type": "MedicalCode", "code": "D000077552", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.407" } } }, { "@type": "MedicalWebPage", "name": "Bévacizumab", "alternateName": "Bevacizumab", "url": "https://questionsmedicales.fr/mesh/D000068258", "about": { "@type": "MedicalCondition", "name": "Bévacizumab", "code": { "@type": "MedicalCode", "code": "D000068258", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.438" } } }, { "@type": "MedicalWebPage", "name": "Brentuximab védotine", "alternateName": "Brentuximab Vedotin", "url": "https://questionsmedicales.fr/mesh/D000079963", "about": { "@type": "MedicalCondition", "name": "Brentuximab védotine", "code": { "@type": "MedicalCode", "code": "D000079963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.469" } } }, { "@type": "MedicalWebPage", "name": "Cétuximab", "alternateName": "Cetuximab", "url": "https://questionsmedicales.fr/mesh/D000068818", "about": { "@type": "MedicalCondition", "name": "Cétuximab", "code": { "@type": "MedicalCode", "code": "D000068818", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.750" } } }, { "@type": "MedicalWebPage", "name": "Daclizumab", "alternateName": "Daclizumab", "url": "https://questionsmedicales.fr/mesh/D000077561", "about": { "@type": "MedicalCondition", "name": "Daclizumab", "code": { "@type": "MedicalCode", "code": "D000077561", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.766" } } }, { "@type": "MedicalWebPage", "name": "Dénosumab", "alternateName": "Denosumab", "url": "https://questionsmedicales.fr/mesh/D000069448", "about": { "@type": "MedicalCondition", "name": "Dénosumab", "code": { "@type": "MedicalCode", "code": "D000069448", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.782" } } }, { "@type": "MedicalWebPage", "name": "Gemtuzumab", "alternateName": "Gemtuzumab", "url": "https://questionsmedicales.fr/mesh/D000079982", "about": { "@type": "MedicalCondition", "name": "Gemtuzumab", "code": { "@type": "MedicalCode", "code": "D000079982", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.790" } } }, { "@type": "MedicalWebPage", "name": "Inotuzumab ozogamicine", "alternateName": "Inotuzumab Ozogamicin", "url": "https://questionsmedicales.fr/mesh/D000080045", "about": { "@type": "MedicalCondition", "name": "Inotuzumab ozogamicine", "code": { "@type": "MedicalCode", "code": "D000080045", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.794" } } }, { "@type": "MedicalWebPage", "name": "Ipilimumab", "alternateName": "Ipilimumab", "url": "https://questionsmedicales.fr/mesh/D000074324", "about": { "@type": "MedicalCondition", "name": "Ipilimumab", "code": { "@type": "MedicalCode", "code": "D000074324", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.798" } } }, { "@type": "MedicalWebPage", "name": "Natalizumab", "alternateName": "Natalizumab", "url": "https://questionsmedicales.fr/mesh/D000069442", "about": { "@type": "MedicalCondition", "name": "Natalizumab", "code": { "@type": "MedicalCode", "code": "D000069442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.813" } } }, { "@type": "MedicalWebPage", "name": "Nivolumab", "alternateName": "Nivolumab", "url": "https://questionsmedicales.fr/mesh/D000077594", "about": { "@type": "MedicalCondition", "name": "Nivolumab", "code": { "@type": "MedicalCode", "code": "D000077594", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.829" } } }, { "@type": "MedicalWebPage", "name": "Omalizumab", "alternateName": "Omalizumab", "url": "https://questionsmedicales.fr/mesh/D000069444", "about": { "@type": "MedicalCondition", "name": "Omalizumab", "code": { "@type": "MedicalCode", "code": "D000069444", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.844" } } }, { "@type": "MedicalWebPage", "name": "Palivizumab", "alternateName": "Palivizumab", "url": "https://questionsmedicales.fr/mesh/D000069455", "about": { "@type": "MedicalCondition", "name": "Palivizumab", "code": { "@type": "MedicalCode", "code": "D000069455", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.860" } } }, { "@type": "MedicalWebPage", "name": "Panitumumab", "alternateName": "Panitumumab", "url": "https://questionsmedicales.fr/mesh/D000077544", "about": { "@type": "MedicalCondition", "name": "Panitumumab", "code": { "@type": "MedicalCode", "code": "D000077544", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.864" } } }, { "@type": "MedicalWebPage", "name": "Ranibizumab", "alternateName": "Ranibizumab", "url": "https://questionsmedicales.fr/mesh/D000069579", "about": { "@type": "MedicalCondition", "name": "Ranibizumab", "code": { "@type": "MedicalCode", "code": "D000069579", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.868" } } }, { "@type": "MedicalWebPage", "name": "Trastuzumab", "alternateName": "Trastuzumab", "url": "https://questionsmedicales.fr/mesh/D000068878", "about": { "@type": "MedicalCondition", "name": "Trastuzumab", "code": { "@type": "MedicalCode", "code": "D000068878", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.875" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ado-trastuzumab emtansine", "alternateName": "Ado-Trastuzumab Emtansine", "url": "https://questionsmedicales.fr/mesh/D000080044", "about": { "@type": "MedicalCondition", "name": "Ado-trastuzumab emtansine", "code": { "@type": "MedicalCode", "code": "D000080044", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.875.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Ado-trastuzumab emtansine", "alternateName": "Ado-Trastuzumab Emtansine", "url": "https://questionsmedicales.fr/mesh/D000080044", "about": { "@type": "MedicalCondition", "name": "Ado-trastuzumab emtansine", "code": { "@type": "MedicalCode", "code": "D000080044", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.875.500" } } }, { "@type": "MedicalWebPage", "name": "Ustékinumab", "alternateName": "Ustekinumab", "url": "https://questionsmedicales.fr/mesh/D000069549", "about": { "@type": "MedicalCondition", "name": "Ustékinumab", "code": { "@type": "MedicalCode", "code": "D000069549", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.200.937" } } }, { "@type": "MedicalWebPage", "name": "Anticorps monoclonaux d'origine murine", "alternateName": "Antibodies, Monoclonal, Murine-Derived", "url": "https://questionsmedicales.fr/mesh/D058846", "about": { "@type": "MedicalCondition", "name": "Anticorps monoclonaux d'origine murine", "code": { "@type": "MedicalCode", "code": "D058846", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.284" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Rituximab", "alternateName": "Rituximab", "url": "https://questionsmedicales.fr/mesh/D000069283", "about": { "@type": "MedicalCondition", "name": "Rituximab", "code": { "@type": "MedicalCode", "code": "D000069283", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.284.785" } } } ] }, { "@type": "MedicalWebPage", "name": "Rituximab", "alternateName": "Rituximab", "url": "https://questionsmedicales.fr/mesh/D000069283", "about": { "@type": "MedicalCondition", "name": "Rituximab", "code": { "@type": "MedicalCode", "code": "D000069283", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.284.785" } } }, { "@type": "MedicalWebPage", "name": "Infliximab", "alternateName": "Infliximab", "url": "https://questionsmedicales.fr/mesh/D000069285", "about": { "@type": "MedicalCondition", "name": "Infliximab", "code": { "@type": "MedicalCode", "code": "D000069285", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.224.642" } } } ] }, { "@type": "MedicalWebPage", "name": "Anticorps antitumoraux", "alternateName": "Antibodies, Neoplasm", "url": "https://questionsmedicales.fr/mesh/D000912", "about": { "@type": "MedicalCondition", "name": "Anticorps antitumoraux", "code": { "@type": "MedicalCode", "code": "D000912", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.240" } } }, { "@type": "MedicalWebPage", "name": "Anticorps neutralisants", "alternateName": "Antibodies, Neutralizing", "url": "https://questionsmedicales.fr/mesh/D057134", "about": { "@type": "MedicalCondition", "name": "Anticorps neutralisants", "code": { "@type": "MedicalCode", "code": "D057134", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.244" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps neutralisants à large spectre", "alternateName": "Broadly Neutralizing Antibodies", "url": "https://questionsmedicales.fr/mesh/D000080908", "about": { "@type": "MedicalCondition", "name": "Anticorps neutralisants à large spectre", "code": { "@type": "MedicalCode", "code": "D000080908", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.244.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Anticorps phospho-spécifiques", "alternateName": "Antibodies, Phospho-Specific", "url": "https://questionsmedicales.fr/mesh/D045163", "about": { "@type": "MedicalCondition", "name": "Anticorps phospho-spécifiques", "code": { "@type": "MedicalCode", "code": "D045163", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.248" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antiprotozoaires", "alternateName": "Antibodies, Protozoan", "url": "https://questionsmedicales.fr/mesh/D000913", "about": { "@type": "MedicalCondition", "name": "Anticorps antiprotozoaires", "code": { "@type": "MedicalCode", "code": "D000913", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.252" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antiviraux", "alternateName": "Antibodies, Viral", "url": "https://questionsmedicales.fr/mesh/D000914", "about": { "@type": "MedicalCondition", "name": "Anticorps antiviraux", "code": { "@type": "MedicalCode", "code": "D000914", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps antideltarétrovirus", "alternateName": "Deltaretrovirus Antibodies", "url": "https://questionsmedicales.fr/mesh/D015480", "about": { "@type": "MedicalCondition", "name": "Anticorps antideltarétrovirus", "code": { "@type": "MedicalCode", "code": "D015480", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.150" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps anti-VIH", "alternateName": "HIV Antibodies", "url": "https://questionsmedicales.fr/mesh/D015483", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-VIH", "code": { "@type": "MedicalCode", "code": "D015483", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.150.440" } } }, { "@type": "MedicalWebPage", "name": "Anticorps anti-HTLVI", "alternateName": "HTLV-I Antibodies", "url": "https://questionsmedicales.fr/mesh/D015481", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-HTLVI", "code": { "@type": "MedicalCode", "code": "D015481", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.150.500" } } }, { "@type": "MedicalWebPage", "name": "Anticorps anti-HTLVII", "alternateName": "HTLV-II Antibodies", "url": "https://questionsmedicales.fr/mesh/D015482", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-HTLVII", "code": { "@type": "MedicalCode", "code": "D015482", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.150.510" } } } ] }, { "@type": "MedicalWebPage", "name": "Anticorps anti-VIH", "alternateName": "HIV Antibodies", "url": "https://questionsmedicales.fr/mesh/D015483", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-VIH", "code": { "@type": "MedicalCode", "code": "D015483", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.150.440" } } }, { "@type": "MedicalWebPage", "name": "Anticorps anti-HTLVI", "alternateName": "HTLV-I Antibodies", "url": "https://questionsmedicales.fr/mesh/D015481", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-HTLVI", "code": { "@type": "MedicalCode", "code": "D015481", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.150.500" } } }, { "@type": "MedicalWebPage", "name": "Anticorps anti-HTLVII", "alternateName": "HTLV-II Antibodies", "url": "https://questionsmedicales.fr/mesh/D015482", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-HTLVII", "code": { "@type": "MedicalCode", "code": "D015482", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.150.510" } } }, { "@type": "MedicalWebPage", "name": "Anticorps de l'hépatite", "alternateName": "Hepatitis Antibodies", "url": "https://questionsmedicales.fr/mesh/D006508", "about": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite", "code": { "@type": "MedicalCode", "code": "D006508", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.450" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps de l'hépatite A", "alternateName": "Hepatitis A Antibodies", "url": "https://questionsmedicales.fr/mesh/D035922", "about": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite A", "code": { "@type": "MedicalCode", "code": "D035922", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.450.251" } } }, { "@type": "MedicalWebPage", "name": "Anticorps de l'hépatite B", "alternateName": "Hepatitis B Antibodies", "url": "https://questionsmedicales.fr/mesh/D006510", "about": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite B", "code": { "@type": "MedicalCode", "code": "D006510", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.450.504" } } }, { "@type": "MedicalWebPage", "name": "Anticorps de l'hépatite C", "alternateName": "Hepatitis C Antibodies", "url": "https://questionsmedicales.fr/mesh/D018937", "about": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite C", "code": { "@type": "MedicalCode", "code": "D018937", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.450.510" } } } ] }, { "@type": "MedicalWebPage", "name": "Anticorps de l'hépatite A", "alternateName": "Hepatitis A Antibodies", "url": "https://questionsmedicales.fr/mesh/D035922", "about": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite A", "code": { "@type": "MedicalCode", "code": "D035922", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.450.251" } } }, { "@type": "MedicalWebPage", "name": "Anticorps de l'hépatite B", "alternateName": "Hepatitis B Antibodies", "url": "https://questionsmedicales.fr/mesh/D006510", "about": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite B", "code": { "@type": "MedicalCode", "code": "D006510", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.450.504" } } }, { "@type": "MedicalWebPage", "name": "Anticorps de l'hépatite C", "alternateName": "Hepatitis C Antibodies", "url": "https://questionsmedicales.fr/mesh/D018937", "about": { "@type": "MedicalCondition", "name": "Anticorps de l'hépatite C", "code": { "@type": "MedicalCode", "code": "D018937", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.254.450.510" } } } ] }, { "@type": "MedicalWebPage", "name": "Autoanticorps", "alternateName": "Autoantibodies", "url": "https://questionsmedicales.fr/mesh/D001323", "about": { "@type": "MedicalCondition", "name": "Autoanticorps", "code": { "@type": "MedicalCode", "code": "D001323", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps anti-protéines citrullinées", "alternateName": "Anti-Citrullinated Protein Antibodies", "url": "https://questionsmedicales.fr/mesh/D000075422", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-protéines citrullinées", "code": { "@type": "MedicalCode", "code": "D000075422", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.095" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antinucléaires", "alternateName": "Antibodies, Antinuclear", "url": "https://questionsmedicales.fr/mesh/D000974", "about": { "@type": "MedicalCondition", "name": "Anticorps antinucléaires", "code": { "@type": "MedicalCode", "code": "D000974", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.204" } } }, { "@type": "MedicalWebPage", "name": "Anticorps antiphospholipides", "alternateName": "Antibodies, Antiphospholipid", "url": "https://questionsmedicales.fr/mesh/D017152", "about": { "@type": "MedicalCondition", "name": "Anticorps antiphospholipides", "code": { "@type": "MedicalCode", "code": "D017152", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.210" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anticorps anticardiolipines", "alternateName": "Antibodies, Anticardiolipin", "url": "https://questionsmedicales.fr/mesh/D017153", "about": { "@type": "MedicalCondition", "name": "Anticorps anticardiolipines", "code": { "@type": "MedicalCode", "code": "D017153", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.210.100" } } } ] }, { "@type": "MedicalWebPage", "name": "Anticorps anticardiolipines", "alternateName": "Antibodies, Anticardiolipin", "url": "https://questionsmedicales.fr/mesh/D017153", "about": { "@type": "MedicalCondition", "name": "Anticorps anticardiolipines", "code": { "@type": "MedicalCode", "code": "D017153", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.210.100" } } }, { "@type": "MedicalWebPage", "name": "Facteur néphritique C3", "alternateName": "Complement C3 Nephritic Factor", "url": "https://questionsmedicales.fr/mesh/D003178", "about": { "@type": "MedicalCondition", "name": "Facteur néphritique C3", "code": { "@type": "MedicalCode", "code": "D003178", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.300" } } }, { "@type": "MedicalWebPage", "name": "Immunoconglutinines", "alternateName": "Immunoconglutinins", "url": "https://questionsmedicales.fr/mesh/D037561", "about": { "@type": "MedicalCondition", "name": "Immunoconglutinines", "code": { "@type": "MedicalCode", "code": "D037561", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.390" } } }, { "@type": "MedicalWebPage", "name": "Immunoglobulines thyréostimulantes", "alternateName": "Immunoglobulins, Thyroid-Stimulating", "url": "https://questionsmedicales.fr/mesh/D018828", "about": { "@type": "MedicalCondition", "name": "Immunoglobulines thyréostimulantes", "code": { "@type": "MedicalCode", "code": "D018828", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.480" } } }, { "@type": "MedicalWebPage", "name": "Facteur rhumatoïde", "alternateName": "Rheumatoid Factor", "url": "https://questionsmedicales.fr/mesh/D012217", "about": { "@type": "MedicalCondition", "name": "Facteur rhumatoïde", "code": { "@type": "MedicalCode", "code": "D012217", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.323.732" } } } ] }, { "@type": "MedicalWebPage", "name": "Abatacept", "alternateName": "Abatacept", "url": "https://questionsmedicales.fr/mesh/D000069594", "about": { "@type": "MedicalCondition", "name": "Abatacept", "code": { "@type": "MedicalCode", "code": "D000069594", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.580.225" } } }, { "@type": "MedicalWebPage", "name": "Isotypes des immunoglobulines", "alternateName": "Immunoglobulin Isotypes", "url": "https://questionsmedicales.fr/mesh/D007132", "about": { "@type": "MedicalCondition", "name": "Isotypes des immunoglobulines", "code": { "@type": "MedicalCode", "code": "D007132", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Immunoglobuline A", "alternateName": "Immunoglobulin A", "url": "https://questionsmedicales.fr/mesh/D007070", "about": { "@type": "MedicalCondition", "name": "Immunoglobuline A", "code": { "@type": "MedicalCode", "code": "D007070", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.026" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Immunoglobuline A sécrétoire", "alternateName": "Immunoglobulin A, Secretory", "url": "https://questionsmedicales.fr/mesh/D007071", "about": { "@type": "MedicalCondition", "name": "Immunoglobuline A sécrétoire", "code": { "@type": "MedicalCode", "code": "D007071", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.026.030" } } } ] }, { "@type": "MedicalWebPage", "name": "Immunoglobuline A sécrétoire", "alternateName": "Immunoglobulin A, Secretory", "url": "https://questionsmedicales.fr/mesh/D007071", "about": { "@type": "MedicalCondition", "name": "Immunoglobuline A sécrétoire", "code": { "@type": "MedicalCode", "code": "D007071", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.026.030" } } }, { "@type": "MedicalWebPage", "name": "Immunoglobuline D", "alternateName": "Immunoglobulin D", "url": "https://questionsmedicales.fr/mesh/D007072", "about": { "@type": "MedicalCondition", "name": "Immunoglobuline D", "code": { "@type": "MedicalCode", "code": "D007072", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.251" } } }, { "@type": "MedicalWebPage", "name": "Immunoglobuline E", "alternateName": "Immunoglobulin E", "url": "https://questionsmedicales.fr/mesh/D007073", "about": { "@type": "MedicalCondition", "name": "Immunoglobuline E", "code": { "@type": "MedicalCode", "code": "D007073", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.312" } } }, { "@type": "MedicalWebPage", "name": "Immunoglobuline G", "alternateName": "Immunoglobulin G", "url": "https://questionsmedicales.fr/mesh/D007074", "about": { "@type": "MedicalCondition", "name": "Immunoglobuline G", "code": { "@type": "MedicalCode", "code": "D007074", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.393" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "LATS", "alternateName": "Long-Acting Thyroid Stimulator", "url": "https://questionsmedicales.fr/mesh/D008135", "about": { "@type": "MedicalCondition", "name": "LATS", "code": { "@type": "MedicalCode", "code": "D008135", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.393.550" } } }, { "@type": "MedicalWebPage", "name": "Muromonab-CD3", "alternateName": "Muromonab-CD3", "url": "https://questionsmedicales.fr/mesh/D016853", "about": { "@type": "MedicalCondition", "name": "Muromonab-CD3", "code": { "@type": "MedicalCode", "code": "D016853", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.393.570" } } }, { "@type": "MedicalWebPage", "name": "Immunoglobuline Rh", "alternateName": "Rho(D) Immune Globulin", "url": "https://questionsmedicales.fr/mesh/D018029", "about": { "@type": "MedicalCondition", "name": "Immunoglobuline Rh", "code": { "@type": "MedicalCode", "code": "D018029", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.393.700" } } } ] }, { "@type": "MedicalWebPage", "name": "LATS", "alternateName": "Long-Acting Thyroid Stimulator", "url": "https://questionsmedicales.fr/mesh/D008135", "about": { "@type": "MedicalCondition", "name": "LATS", "code": { "@type": "MedicalCode", "code": "D008135", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.393.550" } } }, { "@type": "MedicalWebPage", "name": "Muromonab-CD3", "alternateName": "Muromonab-CD3", "url": "https://questionsmedicales.fr/mesh/D016853", "about": { "@type": "MedicalCondition", "name": "Muromonab-CD3", "code": { "@type": "MedicalCode", "code": "D016853", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.393.570" } } }, { "@type": "MedicalWebPage", "name": "Immunoglobuline Rh", "alternateName": "Rho(D) Immune Globulin", "url": "https://questionsmedicales.fr/mesh/D018029", "about": { "@type": "MedicalCondition", "name": "Immunoglobuline Rh", "code": { "@type": "MedicalCode", "code": "D018029", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.393.700" } } }, { "@type": "MedicalWebPage", "name": "Immunoglobuline M", "alternateName": "Immunoglobulin M", "url": "https://questionsmedicales.fr/mesh/D007075", "about": { "@type": "MedicalCondition", "name": "Immunoglobuline M", "code": { "@type": "MedicalCode", "code": "D007075", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.619.574" } } } ] }, { "@type": "MedicalWebPage", "name": "Immunoglobulines par voie veineuse", "alternateName": "Immunoglobulins, Intravenous", "url": "https://questionsmedicales.fr/mesh/D016756", "about": { "@type": "MedicalCondition", "name": "Immunoglobulines par voie veineuse", "code": { "@type": "MedicalCode", "code": "D016756", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.632" } } }, { "@type": "MedicalWebPage", "name": "Anticorps anti-insuline", "alternateName": "Insulin Antibodies", "url": "https://questionsmedicales.fr/mesh/D007330", "about": { "@type": "MedicalCondition", "name": "Anticorps anti-insuline", "code": { "@type": "MedicalCode", "code": "D007330", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.656" } } }, { "@type": "MedicalWebPage", "name": "Alloanticorps", "alternateName": "Isoantibodies", "url": "https://questionsmedicales.fr/mesh/D007518", "about": { "@type": "MedicalCondition", "name": "Alloanticorps", "code": { "@type": "MedicalCode", "code": "D007518", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.664" } } }, { "@type": "MedicalWebPage", "name": "Planticorps", "alternateName": "Plantibodies", "url": "https://questionsmedicales.fr/mesh/D046549", "about": { "@type": "MedicalCondition", "name": "Planticorps", "code": { "@type": "MedicalCode", "code": "D046549", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.820" } } }, { "@type": "MedicalWebPage", "name": "Précipitines", "alternateName": "Precipitins", "url": "https://questionsmedicales.fr/mesh/D011234", "about": { "@type": "MedicalCondition", "name": "Précipitines", "code": { "@type": "MedicalCode", "code": "D011234", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.837" } } }, { "@type": "MedicalWebPage", "name": "Réagines", "alternateName": "Reagins", "url": "https://questionsmedicales.fr/mesh/D011935", "about": { "@type": "MedicalCondition", "name": "Réagines", "code": { "@type": "MedicalCode", "code": "D011935", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.377.715.548.114.890" } } } ], "about": { "@type": "MedicalCondition", "name": "Anticorps", "alternateName": "Antibodies", "code": { "@type": "MedicalCode", "code": "D000906", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Anita Bandrowski", "url": "https://questionsmedicales.fr/author/Anita%20Bandrowski", "affiliation": { "@type": "Organization", "name": "Center for Research in Biological Systems, University of California , La Jolla, CA, USA." } }, { "@type": "Person", "name": "Sophana Chea", "url": "https://questionsmedicales.fr/author/Sophana%20Chea", "affiliation": { "@type": "Organization", "name": "International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia." } }, { "@type": "Person", "name": "Laura Willen", "url": "https://questionsmedicales.fr/author/Laura%20Willen", "affiliation": { "@type": "Organization", "name": "Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States." } }, { "@type": "Person", "name": "Sreynik Nhek", "url": "https://questionsmedicales.fr/author/Sreynik%20Nhek", "affiliation": { "@type": "Organization", "name": "International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia." } }, { "@type": "Person", "name": "Piseth Ly", "url": "https://questionsmedicales.fr/author/Piseth%20Ly", "affiliation": { "@type": "Organization", "name": "International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis.", "datePublished": "2023-03-23", "url": "https://questionsmedicales.fr/article/36952213", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s40259-023-00589-3" } }, { "@type": "ScholarlyArticle", "name": "Subcutaneous infliximab in Crohn's disease patients with previous immunogenic failure of intravenous infliximab.", "datePublished": "2024-09-25", "url": "https://questionsmedicales.fr/article/39317813", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00384-024-04727-3" } }, { "@type": "ScholarlyArticle", "name": "Infliximab therapy in Behçet's uveitis.", "datePublished": "2022-09-20", "url": "https://questionsmedicales.fr/article/36150991", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jfo.2022.04.009" } }, { "@type": "ScholarlyArticle", "name": "Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.", "datePublished": "2022-08-17", "url": "https://questionsmedicales.fr/article/35975641", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5009/gnl220005" } }, { "@type": "ScholarlyArticle", "name": "Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.", "datePublished": "2022-06-03", "url": "https://questionsmedicales.fr/article/35657560", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s40261-022-01162-6" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Globulines", "item": "https://questionsmedicales.fr/mesh/D005916" }, { "@type": "ListItem", "position": 5, "name": "Sérum-globulines", "item": "https://questionsmedicales.fr/mesh/D012712" }, { "@type": "ListItem", "position": 6, "name": "Immunoglobulines", "item": "https://questionsmedicales.fr/mesh/D007136" }, { "@type": "ListItem", "position": 7, "name": "Anticorps", "item": "https://questionsmedicales.fr/mesh/D000906" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Anticorps - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Anticorps", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-04-30", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Anticorps", "description": "Comment détecte-t-on les anticorps dans le sang ?\nQuels tests sont utilisés pour les anticorps spécifiques ?\nLes anticorps peuvent-ils indiquer une infection ?\nQu'est-ce qu'un titre d'anticorps ?\nLes anticorps peuvent-ils être détectés chez les nouveau-nés ?", "url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Infliximab#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Anticorps", "description": "Quels symptômes indiquent une réponse immunitaire ?\nLes anticorps causent-ils des symptômes ?\nComment les anticorps affectent-ils les allergies ?\nLes anticorps peuvent-ils causer des maladies auto-immunes ?\nQuels anticorps sont liés aux infections virales ?", "url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Infliximab#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Anticorps", "description": "Comment les vaccins stimulent-ils la production d'anticorps ?\nLes anticorps peuvent-ils être transférés par le lait maternel ?\nComment maintenir un système immunitaire fort ?\nLes anticorps peuvent-ils être utilisés pour prévenir le COVID-19 ?\nLes anticorps sont-ils efficaces contre toutes les infections ?", "url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Infliximab#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Anticorps", "description": "Comment les anticorps sont-ils utilisés en thérapie ?\nLes anticorps peuvent-ils être administrés par injection ?\nQu'est-ce que l'immunothérapie par anticorps ?\nLes anticorps peuvent-ils être utilisés pour prévenir des maladies ?\nQuels sont les effets secondaires des traitements par anticorps ?", "url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Infliximab#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Anticorps", "description": "Quels sont les risques d'une surproduction d'anticorps ?\nLes anticorps peuvent-ils causer des réactions allergiques ?\nQuelles complications peuvent survenir avec des anticorps monoclonaux ?\nLes anticorps peuvent-ils interférer avec d'autres traitements ?\nQuelles sont les complications des maladies auto-immunes ?", "url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Infliximab#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Anticorps", "description": "Quels facteurs augmentent le risque de maladies auto-immunes ?\nLe stress influence-t-il la production d'anticorps ?\nL'âge influence-t-il la réponse des anticorps ?\nLes infections antérieures affectent-elles la production d'anticorps ?\nLes habitudes alimentaires influencent-elles les anticorps ?", "url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Infliximab#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on les anticorps dans le sang ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des tests sérologiques comme l'ELISA pour mesurer les anticorps." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les anticorps spécifiques ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests comme l'immunofluorescence ou les tests d'agglutination sont utilisés." } }, { "@type": "Question", "name": "Les anticorps peuvent-ils indiquer une infection ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la présence d'anticorps spécifiques peut indiquer une infection antérieure." } }, { "@type": "Question", "name": "Qu'est-ce qu'un titre d'anticorps ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "C'est une mesure de la concentration d'anticorps dans le sang, indiquant l'immunité." } }, { "@type": "Question", "name": "Les anticorps peuvent-ils être détectés chez les nouveau-nés ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les anticorps maternels peuvent être détectés chez les nouveau-nés." } }, { "@type": "Question", "name": "Quels symptômes indiquent une réponse immunitaire ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, fatigue, et inflammation peuvent indiquer une réponse immunitaire active." } }, { "@type": "Question", "name": "Les anticorps causent-ils des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, ce sont les maladies ou infections que les anticorps combattent qui causent des symptômes." } }, { "@type": "Question", "name": "Comment les anticorps affectent-ils les allergies ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les anticorps IgE sont impliqués dans les réactions allergiques, provoquant des symptômes." } }, { "@type": "Question", "name": "Les anticorps peuvent-ils causer des maladies auto-immunes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anticorps peuvent attaquer les tissus sains, entraînant des maladies auto-immunes." } }, { "@type": "Question", "name": "Quels anticorps sont liés aux infections virales ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les anticorps IgM et IgG sont souvent associés aux infections virales." } }, { "@type": "Question", "name": "Comment les vaccins stimulent-ils la production d'anticorps ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccins introduisent des antigènes, entraînant la production d'anticorps spécifiques." } }, { "@type": "Question", "name": "Les anticorps peuvent-ils être transférés par le lait maternel ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les anticorps maternels sont transférés au bébé par le lait maternel, offrant une protection." } }, { "@type": "Question", "name": "Comment maintenir un système immunitaire fort ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée, l'exercice et le sommeil aident à maintenir un système immunitaire fort." } }, { "@type": "Question", "name": "Les anticorps peuvent-ils être utilisés pour prévenir le COVID-19 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements par anticorps monoclonaux sont utilisés pour prévenir les formes graves du COVID-19." } }, { "@type": "Question", "name": "Les anticorps sont-ils efficaces contre toutes les infections ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Non, leur efficacité dépend du type d'infection et de la réponse immunitaire individuelle." } }, { "@type": "Question", "name": "Comment les anticorps sont-ils utilisés en thérapie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des anticorps monoclonaux sont utilisés pour traiter diverses maladies, y compris le cancer." } }, { "@type": "Question", "name": "Les anticorps peuvent-ils être administrés par injection ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les anticorps peuvent être administrés par injection pour traiter certaines maladies." } }, { "@type": "Question", "name": "Qu'est-ce que l'immunothérapie par anticorps ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "C'est un traitement qui utilise des anticorps pour renforcer la réponse immunitaire contre le cancer." } }, { "@type": "Question", "name": "Les anticorps peuvent-ils être utilisés pour prévenir des maladies ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anticorps spécifiques peuvent être administrés pour prévenir certaines infections." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements par anticorps ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des réactions allergiques et des infections." } }, { "@type": "Question", "name": "Quels sont les risques d'une surproduction d'anticorps ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Une surproduction peut entraîner des maladies auto-immunes ou des allergies graves." } }, { "@type": "Question", "name": "Les anticorps peuvent-ils causer des réactions allergiques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains anticorps peuvent provoquer des réactions allergiques en réponse à des allergènes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des anticorps monoclonaux ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des infections, des réactions allergiques et des effets secondaires peuvent survenir." } }, { "@type": "Question", "name": "Les anticorps peuvent-ils interférer avec d'autres traitements ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains anticorps peuvent interagir avec d'autres médicaments, affectant leur efficacité." } }, { "@type": "Question", "name": "Quelles sont les complications des maladies auto-immunes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des dommages aux organes, des infections et une qualité de vie réduite." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de maladies auto-immunes ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs génétiques, environnementaux et hormonaux peuvent augmenter ce risque." } }, { "@type": "Question", "name": "Le stress influence-t-il la production d'anticorps ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affecter la réponse immunitaire et la production d'anticorps." } }, { "@type": "Question", "name": "L'âge influence-t-il la réponse des anticorps ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la réponse des anticorps peut diminuer avec l'âge, rendant les personnes âgées plus vulnérables." } }, { "@type": "Question", "name": "Les infections antérieures affectent-elles la production d'anticorps ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des infections antérieures peuvent influencer la mémoire immunitaire et la production d'anticorps." } }, { "@type": "Question", "name": "Les habitudes alimentaires influencent-elles les anticorps ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en nutriments peut soutenir la production d'anticorps et la santé immunitaire." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 25/04/2025

Contenu vérifié selon les dernières recommandations médicales

Sous-catégories

75 au total
└─

Anticorps anti-idiotypiques

Antibodies, Anti-Idiotypic D000888 - D12.776.377.715.548.114.071
└─

Anticorps anti-archéens

Antibodies, Archaeal D019844 - D12.776.377.715.548.114.107
└─

Anticorps antibactériens

Antibodies, Bacterial D000907 - D12.776.377.715.548.114.125
└─

Anticorps bispécifiques

Antibodies, Bispecific D018033 - D12.776.377.715.548.114.134
└─

Anticorps bloquants

Antibodies, Blocking D019138 - D12.776.377.715.548.114.143
└─

Anticorps catalytiques

Antibodies, Catalytic D017151 - D12.776.377.715.548.114.167
└─

Anticorps antifongiques

Antibodies, Fungal D000908 - D12.776.377.715.548.114.179
└─

Anticorps antihelminthe

Antibodies, Helminth D000909 - D12.776.377.715.548.114.185
└─

Anticorps hétérophiles

Antibodies, Heterophile D000910 - D12.776.377.715.548.114.191
└─

Anticorps monoclonaux

Antibodies, Monoclonal D000911 - D12.776.377.715.548.114.224
└─

Anticorps antitumoraux

Antibodies, Neoplasm D000912 - D12.776.377.715.548.114.240
└─

Anticorps neutralisants

Antibodies, Neutralizing D057134 - D12.776.377.715.548.114.244
└─

Anticorps phospho-spécifiques

Antibodies, Phospho-Specific D045163 - D12.776.377.715.548.114.248
└─

Anticorps antiprotozoaires

Antibodies, Protozoan D000913 - D12.776.377.715.548.114.252
└─

Anticorps antiviraux

Antibodies, Viral D000914 - D12.776.377.715.548.114.254
└─

Autoanticorps

Autoantibodies D001323 - D12.776.377.715.548.114.323
└─

Isotypes des immunoglobulines

Immunoglobulin Isotypes D007132 - D12.776.377.715.548.114.619
└─

Immunoglobulines par voie veineuse

Immunoglobulins, Intravenous D016756 - D12.776.377.715.548.114.632
└─

Anticorps anti-insuline

Insulin Antibodies D007330 - D12.776.377.715.548.114.656
└─

Alloanticorps

Isoantibodies D007518 - D12.776.377.715.548.114.664
└─

Planticorps

Plantibodies D046549 - D12.776.377.715.548.114.820
└─

Précipitines

Precipitins D011234 - D12.776.377.715.548.114.837
└─

Réagines

Reagins D011935 - D12.776.377.715.548.114.890
└─└─

Antistreptolysine

Antistreptolysin D000989 - D12.776.377.715.548.114.125.288
└─└─

Anticorps monoclonaux humanisés

Antibodies, Monoclonal, Humanized D061067 - D12.776.377.715.548.114.224.200
└─└─

Anticorps monoclonaux d'origine murine

Antibodies, Monoclonal, Murine-Derived D058846 - D12.776.377.715.548.114.224.284
└─└─

Infliximab

Infliximab D000069285 - D12.776.377.715.548.114.224.642
└─└─

Anticorps neutralisants à large spectre

Broadly Neutralizing Antibodies D000080908 - D12.776.377.715.548.114.244.500
└─└─

Anticorps antideltarétrovirus

Deltaretrovirus Antibodies D015480 - D12.776.377.715.548.114.254.150
└─└─

Anticorps de l'hépatite

Hepatitis Antibodies D006508 - D12.776.377.715.548.114.254.450
└─└─

Anticorps anti-protéines citrullinées

Anti-Citrullinated Protein Antibodies D000075422 - D12.776.377.715.548.114.323.095
└─└─

Anticorps antinucléaires

Antibodies, Antinuclear D000974 - D12.776.377.715.548.114.323.204
└─└─

Anticorps antiphospholipides

Antibodies, Antiphospholipid D017152 - D12.776.377.715.548.114.323.210
└─└─

Facteur néphritique C3

Complement C3 Nephritic Factor D003178 - D12.776.377.715.548.114.323.300
└─└─

Immunoconglutinines

Immunoconglutinins D037561 - D12.776.377.715.548.114.323.390
└─└─

Immunoglobulines thyréostimulantes

Immunoglobulins, Thyroid-Stimulating D018828 - D12.776.377.715.548.114.323.480
└─└─

Facteur rhumatoïde

Rheumatoid Factor D012217 - D12.776.377.715.548.114.323.732
└─└─

Abatacept

Abatacept D000069594 - D12.776.377.715.548.114.580.225
└─└─

Immunoglobuline A

Immunoglobulin A D007070 - D12.776.377.715.548.114.619.026
└─└─

Immunoglobuline D

Immunoglobulin D D007072 - D12.776.377.715.548.114.619.251
└─└─

Immunoglobuline E

Immunoglobulin E D007073 - D12.776.377.715.548.114.619.312
└─└─

Immunoglobuline G

Immunoglobulin G D007074 - D12.776.377.715.548.114.619.393
└─└─

Immunoglobuline M

Immunoglobulin M D007075 - D12.776.377.715.548.114.619.574
└─└─└─

Adalimumab

Adalimumab D000068879 - D12.776.377.715.548.114.224.200.250
└─└─└─

Alemtuzumab

Alemtuzumab D000074323 - D12.776.377.715.548.114.224.200.375
└─└─└─

Basiliximab

Basiliximab D000077552 - D12.776.377.715.548.114.224.200.407
└─└─└─

Bévacizumab

Bevacizumab D000068258 - D12.776.377.715.548.114.224.200.438
└─└─└─

Brentuximab védotine

Brentuximab Vedotin D000079963 - D12.776.377.715.548.114.224.200.469
└─└─└─

Cétuximab

Cetuximab D000068818 - D12.776.377.715.548.114.224.200.750
└─└─└─

Daclizumab

Daclizumab D000077561 - D12.776.377.715.548.114.224.200.766
└─└─└─

Dénosumab

Denosumab D000069448 - D12.776.377.715.548.114.224.200.782
└─└─└─

Gemtuzumab

Gemtuzumab D000079982 - D12.776.377.715.548.114.224.200.790
└─└─└─

Inotuzumab ozogamicine

Inotuzumab Ozogamicin D000080045 - D12.776.377.715.548.114.224.200.794
└─└─└─

Ipilimumab

Ipilimumab D000074324 - D12.776.377.715.548.114.224.200.798
└─└─└─

Natalizumab

Natalizumab D000069442 - D12.776.377.715.548.114.224.200.813
└─└─└─

Nivolumab

Nivolumab D000077594 - D12.776.377.715.548.114.224.200.829
└─└─└─

Omalizumab

Omalizumab D000069444 - D12.776.377.715.548.114.224.200.844
└─└─└─

Palivizumab

Palivizumab D000069455 - D12.776.377.715.548.114.224.200.860
└─└─└─

Panitumumab

Panitumumab D000077544 - D12.776.377.715.548.114.224.200.864
└─└─└─

Ranibizumab

Ranibizumab D000069579 - D12.776.377.715.548.114.224.200.868
└─└─└─

Trastuzumab

Trastuzumab D000068878 - D12.776.377.715.548.114.224.200.875
└─└─└─

Ustékinumab

Ustekinumab D000069549 - D12.776.377.715.548.114.224.200.937
└─└─└─

Rituximab

Rituximab D000069283 - D12.776.377.715.548.114.224.284.785
└─└─└─

Anticorps anti-VIH

HIV Antibodies D015483 - D12.776.377.715.548.114.254.150.440
└─└─└─

Anticorps anti-HTLVI

HTLV-I Antibodies D015481 - D12.776.377.715.548.114.254.150.500
└─└─└─

Anticorps anti-HTLVII

HTLV-II Antibodies D015482 - D12.776.377.715.548.114.254.150.510
└─└─└─

Anticorps de l'hépatite A

Hepatitis A Antibodies D035922 - D12.776.377.715.548.114.254.450.251
└─└─└─

Anticorps de l'hépatite B

Hepatitis B Antibodies D006510 - D12.776.377.715.548.114.254.450.504
└─└─└─

Anticorps de l'hépatite C

Hepatitis C Antibodies D018937 - D12.776.377.715.548.114.254.450.510
└─└─└─

Anticorps anticardiolipines

Antibodies, Anticardiolipin D017153 - D12.776.377.715.548.114.323.210.100
└─└─└─

Immunoglobuline A sécrétoire

Immunoglobulin A, Secretory D007071 - D12.776.377.715.548.114.619.026.030
└─└─└─

LATS

Long-Acting Thyroid Stimulator D008135 - D12.776.377.715.548.114.619.393.550
└─└─└─

Muromonab-CD3

Muromonab-CD3 D016853 - D12.776.377.715.548.114.619.393.570
└─└─└─

Immunoglobuline Rh

Rho(D) Immune Globulin D018029 - D12.776.377.715.548.114.619.393.700
└─└─└─└─

Ado-trastuzumab emtansine

Ado-Trastuzumab Emtansine D000080044 - D12.776.377.715.548.114.224.200.875.500

Auteurs principaux

Anita Bandrowski

3 publications dans cette catégorie

Affiliations :
  • Center for Research in Biological Systems, University of California , La Jolla, CA, USA.

Sophana Chea

2 publications dans cette catégorie

Affiliations :
  • International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Publications dans "Anticorps" :

Laura Willen

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Sreynik Nhek

2 publications dans cette catégorie

Affiliations :
  • International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Publications dans "Anticorps" :

Piseth Ly

2 publications dans cette catégorie

Affiliations :
  • International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Publications dans "Anticorps" :

Kristina Tang

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

James Oristian

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Roberto Salas-Carrillo

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Aiyana Ponce

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Paola Carolina Valenzuela Leon

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Dara Kong

2 publications dans cette catégorie

Affiliations :
  • International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Publications dans "Anticorps" :

Sokna Ly

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Ratanak Sath

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Chanthap Lon

2 publications dans cette catégorie

Affiliations :
  • International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Rithea Leang

2 publications dans cette catégorie

Affiliations :
  • National Center for Parasitology, Entomology, and Malaria Control, Ministry of Health, Phnom Penh, Cambodia.
  • National Dengue Control Program, Ministry of Health, Phnom Penh, Cambodia.
Publications dans "Anticorps" :

Rekol Huy

2 publications dans cette catégorie

Affiliations :
  • National Center for Parasitology, Entomology, and Malaria Control, Ministry of Health, Phnom Penh, Cambodia.
Publications dans "Anticorps" :

Christina Yek

2 publications dans cette catégorie

Affiliations :
  • International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Jesus G Valenzuela

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Eric Calvo

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Jessica E Manning

2 publications dans cette catégorie

Affiliations :
  • International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :

Sources (624 au total)

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis.

We aimed to assess whether the introduction of the first infliximab biosimilar was associated with changes in overall infliximab consumption (originator and biosimilars) and price changes to the origi... An interrupted time series analysis using infliximab sales data from 2010 to 2020 from the IQVIA Multinational Integrated Data Analysis System for eight selected regions: Australia, Canada, Hong Kong,... Following the introduction of infliximab biosimilars, overall infliximab consumption increased in Australia [immediate change: 0.145 SU/1000 inhabitants (P = 0.014); long-term change: 0.022 SU/1000 in... Introduction of the first infliximab biosimilar was not consistently associated with increased consumption across regions. Additional policy and healthcare system interventions to support biosimilar i...

Subcutaneous infliximab in Crohn's disease patients with previous immunogenic failure of intravenous infliximab.

Immunogenicity is a major reason for secondary loss of response to infliximab (IFX). Recent work suggested potentially lower immunogenicity of subcutaneous (SC) compared to intravenous (IV) IFX. Howev... In a retrospective cohort study conducted at two medical centers, patients with clinically (Harvey-Bradshaw Index ≥ 5) and/or biochemically (fecal calprotectin > 250 µg/g) active Crohn's disease (CD) ... Twenty CD patients were included. The majority of patients (90%) had previous treatment with three or more biologics. Fifteen (75%) and ten (50%) of 20 patients continued IFX SC treatment until months... Subcutaneous infliximab treatment of Crohn's disease patients with previous immunogenic failure of intravenous infliximab was well tolerated and effective in a cohort of patients with refractory Crohn...

Infliximab therapy in Behçet's uveitis.

To evaluate the efficacy of infliximab (IFX) therapy in patients with Behçet's uveitis (BU) refractory to conventional immunomodulatory treatment (IMT).... This study, trial registration number TCTR20200806007, included cases of BU with a minimum of 18 months follow-up on IFX treatment. Demographic characteristics, ophthalmological examination findings, ... Sixty-two eyes of 35 patients on IFX therapy were included in the study. The mean follow-up was 49.5±25.9months. The mean frequency of recurrences during the IMT was 1.47±0.78 (attacks/year), decreasi... IFX is a safe and effective treatment in cases of BU refractory to conventional IMT....

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.

The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn's disease in CT-P13 3.4 study (NCT02096861). We performed a multivariate logistic analysis to demonstrate t... Early serum infliximab trough levels and anti-drug antibody (ADA) levels were compared between CT-P13 (n=100) and originator infliximab (n=98) groups. Receiver operating characteristic (ROC) analysis ... The median infliximab trough levels were not different between CT-P13 and originator infliximab groups at week 6, week 14, and in median ADA levels at week 14, respectively. ROC analysis found an infl... A threshold in serum infliximab trough level at week 6 and week 14 was highly predictive for long-term clinical outcomes. There were no statistical differences in serum infliximab trough levels and AD...

Infliximab for vascular involvement in Behçet's syndrome.

Vascular involvement is an important cause of morbidity and mortality in patients with Behçet's syndrome (BS). We aimed to survey the efficacy and safety of infliximab (IFX) in BS patients with vascul... Charts of all BS patients who used IFX for vascular involvement between 2004 and 2022 were reviewed. Primary endpoint was remission at Month 6, defined as lack of new clinical symptoms and findings as... Among the 127 patients (102 men, mean age at IFX initiation: 35.8 ± 9.0 years) treated with IFX, 110 (87%) had received IFX for remission induction and 87 of these (79%) were already on immunosuppress... Infliximab seems to be effective in majority of BS patients with vascular involvement, even in those who are refractory to immunosuppressives and glucocorticoids....

Infliximab as a potential treatment for COVID-19.

As the third year of the SARS-CoV-2 pandemic approaches, COVID-19 continues to cause substantial morbidity and mortality due to waning vaccine efficacy and the emergence of new, highly contagious subv... Hospitalized patients who develop hypoxia due to SARS-CoV-2 infection are typically treated with an antiviral agent, remdesivir, as well as an immunomodulator, dexamethasone, but mortality rates for s... On 2 June 2022, the United States National Institutes of Health reported results from a large, randomized placebo-controlled clinical trial known as ACTIV-1. The study found a mortality benefit and su...

Infliximab Rescue Therapy in Pediatric Severe Colitis.

Clinical remission has been achieved with infliximab in patients with refractory ulcerative colitis (UC). However, there is conflicting data regarding its effectiveness as rescue therapy in adult acut... A single-institution, retrospective review was conducted of pediatric patients with UC or indeterminate colitis who received inpatient rescue infliximab therapy from 1/2000 to 1/2019. Rescue inflixima... Thirty patients met inclusion criteria. The median age at administration of rescue infliximab treatment was 14 years [IQR 13,17]. Rescue therapy with infliximab was successful in 33% (n = 10), while 6... In severe acute ulcerative or indeterminate colitis cases where infliximab has not been previously used, rescue infliximab can be used to avoid colectomy but has a high failure rate.... IV.... Retrospective study....

Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.

Cyclophosphamide and infliximab are recommended as induction therapies for severe Behçet's syndrome. Whether infliximab is safer and more effective than cyclophosphamide in treating severe Behçet's sy... In this phase 2, Bayesian, multicenter randomized controlled trial, we assigned patients fulfilling the International Study Group's criteria for Behçet's syndrome who had major vascular or central ner... Between May 2018 and April 2021, 52 patients with severe Behçet's syndrome (n=37 [71%] with vascular Behçet's syndrome and n=15 [29%] with neuro-Behçet's syndrome) were randomly assigned to receive ei... Among patients with severe Behçet's syndrome, induction therapy with infliximab had a superior complete response rate at 22 weeks and fewer adverse events than induction with cyclophosphamide. (Funded...